Want to see ABSI full AI Analyst Report?
ABSI Stock Chart & Stats
$3.58
$0.12(3.91%)
At close: 4:00 PM EST
$3.58
$0.12(3.91%)
Day’s Range― - ―
52-Week Range$2.24 - $12.06
Previous CloseN/A
Volume51.94M
Average Volume (3M)6.66M
Market Cap
$1.41B
Enterprise Value$337.60
Total Cash (Recent Filing)$125.70M
Total Debt (Recent Filing)$4.42M
Price to Earnings (P/E)―
Beta2.28
Next Earnings
Aug 11, 2026EPS Estimate
-0.19Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.83
Shares Outstanding169,400,330
10 Day Avg. Volume4,429,233
30 Day Avg. Volume6,656,492
Financial Highlights & Ratios
PEG Ratio0.39
Price to Book (P/B)2.52
Price to Sales (P/S)170.48
P/FCF Ratio-5.08
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit>-0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$13.38Price Target Upside273.60% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering9
EPS Forecast (FY)-0.75
Revenue Forecast (FY)$5.69M
Bulls Say, Bears Say
Bulls Say
Low Leverage Balance SheetVery low debt relative to equity materially reduces refinancing and solvency risk for a pre-revenue biotech. This balance-sheet strength provides durable optionality to fund multi-year R&D programs, pursue partnerships or raise capital under less stressed conditions, supporting program continuity.
AI Platform And Pipeline LeverageDemonstrated platform leverage (AI + wet-lab) that can generate multiple programs and services deals is a structural strength. Ability to spin out additional antibody assets and attract partnerships supports recurring collaboration revenue and long-term scalability of R&D productivity.
Favorable Early Clinical PK/safetyEarly human data showing clean safety and long half-life (supports twice- or thrice-yearly dosing) increases commercial differentiation and adherence potential. Combined with defined POC timelines, this durable clinical profile strengthens partner interest and long-term marketability if efficacy is confirmed.
Bears Say
High Cash BurnSustained, large negative operating and free cash flows create structural funding pressure for a pre-revenue biotech. Persistent burn increases reliance on capital markets or partnerships, raises dilution risk, and constrains flexibility to expand programs without new financing.
Very Limited Revenue BaseRevenue is negligible relative to costs and has declined materially, indicating the services/collaboration model has not yet produced scalable cash inflows. A tiny revenue base lengthens dependence on external funding and makes operating leverage and margin sustainability distant objectives.
Clinical And Regulatory Execution RiskCore value hinges on upcoming efficacy readouts and regulatory decisions; directional interim data and known placebo issues in endometriosis mean trial outcomes are uncertain. Negative or equivocal results would materially delay commercialization, partnerships, and milestone revenue.
AbSci News
ABSI FAQ
What was Absci Corp.’s price range in the past 12 months?
Absci Corp. lowest stock price was $2.24 and its highest was $12.05 in the past 12 months.
What is Absci Corp.’s market cap?
Absci Corp.’s market cap is $1.41B.
When is Absci Corp.’s upcoming earnings report date?
Absci Corp.’s upcoming earnings report date is Aug 11, 2026 which is in 19 days.
How were Absci Corp.’s earnings last quarter?
Absci Corp. released its earnings results on May 07, 2026. The company reported -$0.19 earnings per share for the quarter, beating the consensus estimate of -$0.199 by $0.009.
Is Absci Corp. overvalued?
According to Wall Street analysts Absci Corp.’s price is currently Undervalued.
Does Absci Corp. pay dividends?
Absci Corp. does not currently pay dividends.
What is Absci Corp.’s EPS estimate?
Absci Corp.’s EPS estimate is -0.19.
How many shares outstanding does Absci Corp. have?
Absci Corp. has 169,400,330 shares outstanding.
What happened to Absci Corp.’s price movement after its last earnings report?
Absci Corp. reported an EPS of -$0.19 in its last earnings report, beating expectations of -$0.199. Following the earnings report the stock price went up 2.609%.
Which hedge fund is a major shareholder of Absci Corp.?
Currently, no hedge funds are holding shares in ABSI
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
AbSci Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$13.38 (273.60% Upside)
$13.38 (273.60% Upside)
Blogger Sentiment
Bullish
ABSI Sentiment 70%
Sector Average 66%
Sector Average 66%
Insider Transactions
Bought Shares
Worth $349.6K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Neutral
Last 7 Days ▼ 3.7%
Last 30 Days ▲ 3.8%
Last 30 Days ▲ 3.8%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
137.03%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-15.85%
Trailing 12-Months
Company Description
Absci Corp.
Absci Corporation operates as a biopharmaceutical company primarily focused on discovering novel drug targets and developing new therapeutic compounds. Leveraging its distinctive integrated drug creation platform, the firm generates potential biologic medicines and essential cell lines for manufacturing, which it provides to its collaborators, predominantly within the United States. This advanced platform is instrumental in facilitating the development of biologics by meticulously integrating the traditionally separate stages of drug discovery and cell line engineering into one streamlined process. Absci Corporation was founded in 2011 and is based in Vancouver, Washington.
ABSI Stock 12 Month Forecast
Average Price Target
$13.38
▲(273.60% Upside)
Technical Analysis
Autolus Therapeutics
―
―
ADC Therapeutics
―
4D Molecular Therapeutics
―
Design Therapeutics
―
Ownership Overview
6.13% Insiders
17.83% Mutual Funds
0.09% Other Institutional Investors
56.23% Public Companies and
Individual Investors